

## Special Issue

# Inflammatory Bowel Disease and Infection

### Message from the Guest Editor

The connection between inflammatory bowel disease (IBD) and infections was established soon after the classification of both Crohn's disease (CD) and ulcerative colitis (UC). It is now clear that infections play an important role in pathogenesis, clinical course, and disease exacerbations during IBD. Moreover, the disease itself predisposes patients to various infections, and the infection risk rises even higher during therapy, as the most commonly used medications induce immunomodulation and inhibition. Hence, various drugs have been shown to expose patients to specific infectious agents (e.g., tuberculosis, herpes zoster). Furthermore, immunomodulation affects response to vaccinations, thus further increasing patients' exposure to infections. As a consequence, national and international guidelines support screening tests, pretreatment vaccinations, and prophylactic therapy for specific cases. Gathering new information on any of these subjects may lead to a better understanding of the mechanism and risk factors and may help in risk stratification and the development of new therapeutic and prophylactic approaches

---

### Guest Editor

Dr. Adi Lahat

Department of Gastroenterology, Samson Assuta Ashdod Medical Center, Affiliated with Faculty of Medicine, Ben Gurion University of the Negev, Be'er Sheva, Israel

---

### Deadline for manuscript submissions

closed (27 January 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/89603](https://mdpi.com/si/89603)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).